

IMMUCELL CORP /DE/  
Form 8-K  
March 20, 2014

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report: March 19, 2014  
(Date of earliest event reported)

ImmuCell Corporation  
(Exact name of registrant as specified in its charter)

|  |                                       |   |
|--|---------------------------------------|---|
| DE<br>(State or other jurisdiction<br>of incorporation)                              | 001-12934<br>(Commission File Number) | 01-0382980<br>(IRS Employer<br>Identification Number) |
| 56 Evergreen Drive<br>Portland, Maine<br>(Address of principal executive<br>offices) |                                       | 04103<br>(Zip Code)                                   |

207-878-2770  
(Registrant's telephone number, including area code)

Not Applicable  
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 5.05 – Amendments to the Registrant’s Code of Ethics, or Waiver of a Provision of the Code of Ethics

On March 19, 2014, the Company’s Board of Directors approved several revisions and improvements to its Code of Business Conduct and Ethics. These changes principally clarify and update the sections entitled, “Relationship with Clients, Suppliers, Prospective Business Associates and Government Officials” and “Privacy and Confidentiality” as well as make several administrative amendments. It is company policy to review this policy periodically and file it with the SEC approximately every five years.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 20, 2014

IMMUCELL CORPORATION

By: /s/Michael F Brigham  
Michael F. Brigham  
President and CEO

---

Exhibit Index

| Exhibit<br>No. | Description  |
|----------------|--|
| <u>EX-14</u>   | Code of Business Conduct and Ethics for ImmuCell Corporation |

---

---